Financial reports
10-Q
2024 Q2
Quarterly report
14 Feb 24
10-Q
2024 Q1
Quarterly report
14 Nov 23
10-K
2023 FY
Annual report
12 Oct 23
NT 10-K
Notice of late annual filing
29 Sep 23
10-Q
2023 Q3
Quarterly report
11 May 23
10-Q
2023 Q2
Quarterly report
21 Feb 23
NT 10-Q
Notice of late quarterly filing
15 Feb 23
10-Q
2023 Q1
Quarterly report
14 Nov 22
10-K
2022 FY
Annual report
27 Sep 22
Current reports
8-K
Aytu BioPharma Reports Record ADHD Revenue and Operating
14 Feb 24
8-K
Entry into a Material Definitive Agreement
17 Nov 23
8-K
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
14 Nov 23
8-K
Aytu BioPharma Announces Approval of the Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement
26 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Results of Operations and Financial Condition
27 Sep 23
8-K
Departure of Directors or Certain Officers
15 Aug 23
8-K
Regulation FD Disclosure
31 Jul 23
8-K
Aytu BioPharma Announces Submission of Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement
10 Jul 23
8-K
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
12 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
23 Jun 23
424B4
Prospectus supplement with pricing info
12 Jun 23
FWP
Free writing prospectus
9 Jun 23
FWP
Free writing prospectus
6 Jun 23
S-1/A
IPO registration (amended)
5 Jun 23
S-1
IPO registration
1 May 23
424B5
Prospectus supplement for primary offering
14 Nov 22
424B5
Prospectus supplement for primary offering
10 Aug 22
424B5
Prospectus supplement for primary offering
8 Aug 22
S-3
Shelf registration
8 Jun 22
Proxies
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Sep 22
DEFA14A
Additional proxy soliciting materials
21 Sep 22
DEF 14A
Definitive proxy
25 Aug 22
PRE 14A
Preliminary proxy
15 Aug 22
DEFA14A
Additional proxy soliciting materials
7 Apr 22
DEF 14A
Definitive proxy
7 Apr 22
DEFA14A
Additional proxy soliciting materials
20 May 21
DEFA14A
Additional proxy soliciting materials
20 May 21
Other
EFFECT
Notice of effectiveness
9 Jun 23
CORRESP
Correspondence with SEC
7 Jun 23
CORRESP
Correspondence with SEC
7 Jun 23
CT ORDER
Confidential treatment order
16 May 23
EFFECT
Notice of effectiveness
23 Jun 22
CORRESP
Correspondence with SEC
16 Jun 22
UPLOAD
Letter from SEC
13 Jun 22
UPLOAD
Letter from SEC
23 Feb 22
CORRESP
Correspondence with SEC
22 Feb 22
UPLOAD
Letter from SEC
17 Feb 22
Ownership